Since there was a clear correlation between the CD44+/CD24- status and the basal-like tumor subtype, we extended the immunohistochemical analysis to an additional TMA including tumors from BRCA1 hereditary breast cancer patients, known to be of predominantly basal-like phenotype [9]. The gene discussed is CD44; the disease is breast carcinoma.